LoL's ARAM Mayhem mode is getting some significant updates in the 26.03 PBE, with new progession meta progress, new augments, and sets too.

Hi! If you’re finding value in our Applied AI newsletter, I encourage you to consider subscribing to The Information. It ...

Wondering if Recursion Pharmaceuticals at around US$4.67 a share is priced for its potential or still misunderstood by the market? This article walks through what the current numbers may be telling ...

Recursion Pharmaceuticals has reported updated data from its ELUCIDATE & TUPELO trials, but the stock has failed to mount a ...

The site, which will cost about €10.0 billion ($11.7 billion) to complete, will be the third-largest of the company’s Verbund ...

Nvidia is turning its AI firepower toward the hardest problems in medicine, striking multibillion-dollar alliances with ...

Explore the impact of drug discovery automation in 2026, addressing complexity and improving decision-making across ...

We recently published 10 Stocks With Massive Gains; 5 at Record Highs. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was one of the top performers on Wednesday. Recursion extended its winning streak ...

Author Shawn Peters blends clarity and rigor to make data structures and algorithms accessible to all learners. COLORADO, CO, UNITED STATES, January 2, 2026 /EINPresswire.com/ — Vibrant Publishers ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the 12 Best Genomics Stocks to Invest In. Cathie Wood’s ARK Investment acquired 755,000 shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...